Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.
暂无分享,去创建一个
Lynne Peeples | David Katzenstein | Victoria A Johnson | Belinda Ha | D. Katzenstein | V. Johnson | P. Sax | E. Daar | A. Collier | M. Fischl | S. Koletar | B. Ha | J. Rooney | C. Godfrey | K. Mollan | James F Rooney | Margaret A Fischl | Ann C Collier | Paul E Sax | Eric S Daar | Camlin Tierney | P. Geiseler | Catherine Godfrey | Susan L Koletar | Katie Mollan | Nasreen C Jahed | Laurie Myers | Awny Farajallah | William C Woodward | P Jan Geiseler | Nasreen C. Jahed | C. Tierney | Lynne Peeples | N. Jahed | Laurie Myers | A. Farajallah | W. Woodward
[1] Joel E Gallant,et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. , 2004, JAMA.
[2] D. Richman,et al. 2022 update of the drug resistance mutations in HIV-1. , 2022, Topics in antiviral medicine.
[3] Joel E Gallant,et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. , 2006, The New England journal of medicine.
[4] B. Gazzard,et al. British HIV Association (BHIVA) guidelines for the treatment of HIV‐infected adults with antiretroviral therapy (2005) , 2005, HIV medicine.
[5] C. Leen,et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy , 2006, AIDS.
[6] J. van Lunzen,et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48 , 2008, AIDS.
[7] Peter Reiss,et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. , 2008, JAMA.
[8] D. Fine,et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment , 2009, AIDS.
[9] Colombe Chappey,et al. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. , 2003, The Journal of infectious diseases.
[10] N. Ghoraf. Reliability formula & limit law of the failure time of “m-consecutive-k-out-of-n:F system” , 2008 .
[11] Amalio Telenti,et al. Antiretroviral Treatment of Adult HIV Infection2010 Recommendations of the International AIDS Society–USA Panel , 2010 .
[12] S. Hammer,et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. , 2001, JAMA.
[13] J. J. Henning,et al. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.
[14] Steve A Castillo,et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] J. Montaner,et al. Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients. , 2004, The Journal of infectious diseases.
[16] I. Sanne,et al. Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients. , 2003, The Journal of infectious diseases.
[17] Huldrych F Günthard,et al. Update of the drug resistance mutations in HIV-1: Spring 2008. , 2008, Topics in HIV medicine : a publication of the International AIDS Society, USA.
[18] B. Gazzard. British HIV Association guidelines for the treatment of HIV‐1‐infected adults with antiretroviral therapy 2008 , 2005, HIV medicine.